Scott Tyler Aaronson
Chief Science Officer, Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt; Adjunct Professor of Psychiatry, University of Maryland School of Medicine
Key Impact
He is a leading psychiatrist in treatment-resistant depression and a key investigator on psilocybin studies, including work on preparation, dosing, outcomes, and mechanisms of psychedelic-assisted therapy.
Background & Research
Scott T. Aaronson, MD, is a psychiatrist specializing in treatment-resistant affective disorders and psychedelic-assisted treatment research. He serves as Chief Science Officer of the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt and is an Adjunct Professor of Psychiatry at the University of Maryland School of Medicine. His work has focused on novel interventions for severe depression, including psilocybin and neurostimulation.
Collaboration Network
28 collaborators· click a node to visit their profile
Full network →